Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
- Conditions
- Small Cell Carcinoma, Hypercalcaemic TypeOvarian Cancer
- Interventions
- Registration Number
- NCT05368207
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
- Detailed Description
It is an open-label single patient Clinical Trial to be conducted at Princess Margaret Cancer Centre for a patient with Small Cell Carcinoma of Ovary - Hypercalcemic Type (SCCOHT) who has rare and aggressive malignancy with no current consensus on treatment approach and surveillance.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1
- Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
- N/A
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Pembrolizumab Pembrolizumab Pembrolizumab will be given as an intravenous infusion at 200 mg, every 6 weeks, for 6 cycles.
- Primary Outcome Measures
Name Time Method Progression free survival 2 years Determined by CT scans
- Secondary Outcome Measures
Name Time Method overall performance status 2 years Eastern cooperative oncology group (ECOG) score, patient-reported symptoms as well as objective measurements by CT scans.
Exploratory Endpoint 2 Years Exploratory Endpoint will be measured by circulating DNA to monitor minimal residual disease
Objective evidence of response to treatment 2 years Recorded with CA-125 every 6 weeks and CT scans after every 2 cycles of treatment
Trial Locations
- Locations (1)
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Princess Margaret Cancer Centre🇨🇦Toronto, Ontario, Canada